|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and
Bray F: Cancer incidence and mortality patterns in Europe:
Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Niinivirta M, Enblad G, Lindskog C, Ponten
F, Dragomir A and Ullenhag GJ: Tumoral pyruvate kinase l/r as a
predictive marker for the treatment of renal cancer patients with
sunitinib and sorafenib. J Cancer. 10:3224–3231. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huff T, Muller CS, Otto AM, Netzker R and
Hannappel E: beta-Thymosins, small acidic peptides with multiple
functions. Int J Biochem Cell Biol. 33:205–220. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sribenja S, Wongkham S, Wongkham C, Yao Q
and Chen C: Roles and mechanisms of β-thymosins in cell migration
and cancer metastasis: An update. Cancer Invest. 31:103–110. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen C, Li M, Yang H, Chai H, Fisher W and
Yao Q: Roles of thymosins in cancers and other organ systems. World
J Surg. 29:264–270. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hsiao HL, Wang WS, Chen PM and Su Y:
Overexpression of thymosin beta-4 renders SW480 colon carcinoma
cells more resistant to apoptosis triggered by FasL and two
topoisomerase II inhibitors via downregulating Fas and upregulating
Survivin expression, respectively. Carcinogenesis. 27:936–944.
2006. View Article : Google Scholar
|
|
9
|
Huang HC, Hu CH, Tang MC, Wang WS, Chen PM
and Su Y: Thymosin beta4 triggers an epithelial-mesenchymal
transition in colorectal carcinoma by upregulating integrin-linked
kinase. Oncogene. 26:2781–2790. 2007. View Article : Google Scholar
|
|
10
|
Kobayashi T, Okada F, Fujii N, Tomita N,
Ito S, Tazawa H, Aoyama T, Choi SK, Shibata T, Fujita H and
Hosokawa M: Thymosin-beta4 regulates motility and metastasis of
malignant mouse fibrosarcoma cells. Ame J Pathol. 160:869–882.
2002. View Article : Google Scholar
|
|
11
|
Larsson LI and Holck S: Occurrence of
thymosin beta4 in human breast cancer cells and in other cell types
of the tumor microen-vironment. Hum Pathol. 38:114–119. 2007.
View Article : Google Scholar
|
|
12
|
Wang WS, Chen PM, Hsiao HL, Ju SY and Su
Y: Overexpression of the thymosin beta-4 gene is associated with
malignant progression of SW480 colon cancer cells. Oncogene.
22:3297–3306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang ZY, Zeng FQ, Zhu ZH, Jiang GS, Lv L,
Wan F, Dong R, Xiao XY and Xing SA: Evaluation of thymosin β4 in
the regulation of epithelial-mesenchymal transformation in
urothelial carcinoma. Urol Oncol. 30:167–176. 2012. View Article : Google Scholar
|
|
14
|
Zhang Y, Feurino LW, Zhai Q, Wang H,
Fisher WE, Chen C, Yao Q and Li M: Thymosin Beta 4 is overexpressed
in human pancreatic cancer cells and stimulates proinflammatory
cytokine secretion and JNK activation. Cancer Biol Ther. 7:419–423.
2008. View Article : Google Scholar
|
|
15
|
Chakravatri A, Zehr EM, Zietman AL,
Shipley WU, Goggins WB, Finkelstein DM, Young RH, Chang EL and Wu
CL: Thymosin beta-15 predicts for distant failure in patients with
clinically localized prostate cancer-results from a pilot study.
Urology. 55:635–638. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Feher LZ, Pocsay G, Krenacs L, Zvara A,
Bagdi E, Pocsay R, Lukács G, Győry F, Gazdag A, Tarkó E and Puskás
LG: Amplification of thymosin beta 10 and AKAP13 genes in
metastatic and aggressive papillary thyroid carcinomas. Pathol
Oncol Res. 18:449–458. 2012. View Article : Google Scholar
|
|
17
|
Gu Y, Wang C, Wang Y, Qiu X and Wang E:
Expression of thymosin beta10 and its role in non-small cell lung
cancer. Hum Pathol. 40:117–124. 2009. View Article : Google Scholar
|
|
18
|
Santelli G, Bartoli PC, Giuliano A,
Porcellini A, Mineo A, Barone MV, Busiello I, Trapasso F, Califano
D and Fusco A: Thymosin beta-10 protein synthesis suppression
reduces the growth of human thyroid carcinoma cells in semisolid
medium. Thyroid. 12:765–772. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song C, Su Z and Guo J: Thymosin β 10 is
overexpressed and associated with unfavorable prognosis in
hepatocellular carcinoma. Biosci Rep. 39:pii: BSR20182355. 2019.
View Article : Google Scholar
|
|
20
|
Zhang X, Ren D, Guo L, Wang L, Wu S, Lin
C, Ye L, Zhu J, Li J, Song L, et al: Thymosin beta 10 is a key
regulator of tumorigen-esis and metastasis and a novel serum marker
in breast cancer. Breast Cancer Res. 19:152017. View Article : Google Scholar
|
|
21
|
Lee SH, Zhang W, Choi JJ, Cho YS, Oh SH,
Kim JW, Hu L, Xu J, Liu J and Lee JH: Overexpression of the
thymosin beta-10 gene in human ovarian cancer cells disrupts
F-actin stress fiber and leads to apoptosis. Oncogene.
20:6700–6706. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sribenja S, Sawanyawisuth K, Kraiklang R,
Wongkham C, Vaeteewoottacharn K, Obchoei S, Yao Q, Wongkham S and
Chen C: Suppression of thymosin β10 increases cell migration and
metastasis of cholangiocarcinoma. BMC Cancer. 13:4302013.
View Article : Google Scholar
|
|
23
|
Wozniak MB, Le Calvez-Kelm F,
Abedi-Ardekani B, Byrnes G, Durand G, Carreira C, Michelon J,
Janout V, Holcatova I, Foretova L, et al: Integrative genome-wide
gene expression profiling of clear cell renal cell carcinoma in
Czech Republic and in the United States. PLoS One. 8:e578862013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gerlinger M, Horswell S, Larkin J, Rowan
AJ, Salm MP, Varela I, Fisher R, McGranahan N, Matthews N, Santos
CR, et al: Genomic architecture and evolution of clear cell renal
cell carcinomas defined by multiregion sequencing. Nat Genet.
46:225–233. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
von Roemeling CA, Radisky DC, Marlow LA,
Cooper SJ, Grebe SK, Anastasiadis PZ, Tun HW and Copland JA:
Neuronal pentraxin 2 supports clear cell renal cell carcinoma by
activating the AMPA-selective glutamate receptor-4. Cancer Res.
74:4796–4810. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Nam HY, Chandrashekar DS, Kundu A, Shelar
S, Kho EY, Sonpavde G, Naik G, Ghatalia P, Livi CB, Varambally S
and Sudarshan S: Integrative epigenetic and gene expression
analysis of renal tumor progression to metastasis. Mol Cancer Res.
17:84–96. 2019. View Article : Google Scholar
|
|
27
|
Jones J, Out H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar
|
|
29
|
Cao Q, Ruan H, Wang K, Song Z, Bao L, Xu
T, Xiao H, Wang C, Cheng G, Tong J, et al: Overexpression of PLIN2
is a prognostic marker and attenuates tumor progression in clear
cell renal cell carcinoma. Int J Oncol. 53:137–147. 2018.PubMed/NCBI
|
|
30
|
Yusenko MV, Zubakov D and Kovacs G: Gene
expression profiling of chromophobe renal cell carcinomas and renal
onco-cytomas by Affymetrix GeneChip using pooled and individual
tumours. Int J Biol Sci. 5:517–527. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lenburg ME, Liou LS, Gerry NP, Frampton
GM, Cohen HT and Christman MF: Previously unidentified changes in
renal cell carcinoma gene expression identified by parametric
analysis of microarray data. BMC Cancer. 3:312003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jones J, Out H, Spentzos D, Kolia S, Inan
M, Beecken WD, Fellbaum C, Gu X, Joseph M, Pantuck AJ, et al: Gene
signatures of progression and metastasis in renal cell cancer. Clin
Cancer Res. 11:5730–5739. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gumz ML, Zou H, Kreinest PA, Childs AC,
Belmonte LS, LeGrand SN, Wu KJ, Luxon BA, Sinha M, Parker AS, et
al: Secreted frizzled-related protein 1 loss contributes to tumor
phenotype of clear cell renal cell carcinoma. Clin Cancer Res.
13:4740–4749. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Beroukhim R, Brunet JP, Di Napoli A, Mertz
KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, et
al: Patterns of gene expression and copy-number alterations in
von-hippel lindau disease-associated and sporadic clear cell
carcinoma of the kidney. Cancer Res. 69:4674–4681. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang T, Niu X, Liao L, Cho EA and Yang H:
The contributions of HIF-target genes to tumor growth in RCC. PLoS
One. 8:e805442013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Campagna R, Cecati M, Pozzi V, Fumarola S,
Pompei V, Milanese G, Galosi AB, Sartini D and Emanuelli M:
Involvement of transforming growth factor beta 1 in the
transcriptional regulation of nicotinamide N-methyltransferase in
clear cell renal cell carcinoma. Cell Mol Biol. 64:51–55. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tang SW, Yang TC, Lin WC, Chang WH, Wang
CC, Lai MK and Lin JY: Nicotinamide N-methyltransferase induces
cellular invasion through activating matrix metalloproteinase-2
expression in clear cell renal cell carcinoma cells.
Carcinogenesis. 32:138–145. 2011. View Article : Google Scholar
|
|
38
|
Pan Y, Wu Y, Hu J, Shan Y, Ma J, Ma H, Qi
X and Jia L: Long noncoding RNA HOTAIR promotes renal cell
carcinoma malignancy through alpha-2, 8-sialyltransferase 4 by
sponging microRNA-124. Cell Prolif. 51:e125072018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiappetta G, Pentimalli F, Monaco M,
Fedele M, Pasquinelli R, Pierantoni GM, Ribecco MT, Santelli G,
Califano D, Pezzullo L and Fusco A: Thymosin beta-10 gene
expression as a possible tool in diagnosis of thyroid neoplasias.
Oncol Rep. 12:239–243. 2004.PubMed/NCBI
|
|
40
|
Verghese-Nikolakaki S, Apostolikas N,
Livaniou E, Ithakissios DS and Evangelatos GP: Preliminary findings
on the expression of thymosin beta-10 in human breast cancer. Br J
Cancer. 74:1441–1444. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Hall AK: Differential expression of
thymosin genes in human tumors and in the developing human kidney.
Int J Cncer. 48:672–677. 1991. View Article : Google Scholar
|
|
42
|
Hall AK: Amplification-independent
overexpression of thymosin beta-10 mRNA in human renal cell
carcinoma. Ren Fail. 16:243–254. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lee SH, Son MJ, Oh SH, Rho SB, Park K, Kim
YJ, Park MS and Lee JH: Thymosin {beta}(10) inhibits angiogenesis
and tumor growth by interfering with Ras function. Cancer Res.
65:137–148. 2005.PubMed/NCBI
|
|
44
|
Zhang T, Li X, Yu W, Yan Z, Zou H and He
X: Overexpression of thymosin beta-10 inhibits VEGF mRNA
expression, autocrine VEGF protein production, and tube formation
in hypoxia-induced monkey choroid-retinal endothelial cells.
Ophthalmic Res. 41:36–43. 2009. View Article : Google Scholar
|
|
45
|
Ryu YK, Lee YS, Lee GH, Song KS, Kim YS
and Moon EY: Regulation of glycogen synthase kinase-3 by thymosin
beta-4 is associated with gastric cancer cell migration. Int J
Cancer. 131:2067–2077. 2012. View Article : Google Scholar : PubMed/NCBI
|
